Director/PDMR Shareholding
Faron Pharmaceuticals Ltd. announced that Yrjö Wichmann, a Senior Advisor, acquired 10,000 ordinary shares on March 17, 2026, at a price of EUR 0.51942 per share. This transaction, totaling EUR 5,194.20, was conducted on the Nasdaq First North Growth Market. This insider purchase may signal confidence in the company's future prospects.
Select text to share a quote on X · sign in to keep highlights & notes in your FARN notes
| Faron Pharmaceuticals Ltd | Company announcement | March 19, 2026 at 09:05:00 EET |
TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Yrjö Wichmann, other senior manager of the Company, acquired 10,000 ordinary shares in Faron at price of EUR 0.51942 per share on 17 March 2026.
Further details are set out in the Notification of Dealing Form below.
| a. | Name | Yrjö Wichmann |
| 2 | Reason for notification | |
| a. | Position/Status | Senior Advisor |
| b. | Initial notification/ Amendment | Initial Notification |
| a. | Name | Faron Pharmaceuticals Ltd. |
| b. | LEI | 7437009H31TO1DC0EB42 |
| c. | Reference number | 147958/5/4 |
| a. | Description of the financial instrument, type of instrument Identification Code | Share ISIN: FI4000153309 |
| b. | Nature of the transaction | Acquisition |
| Price(s) per share (p) | Volume(s) | |
| 0.51942 | 10,000 | |
| d. | Aggregated information Volume Price | Transaction details (a) (1): Volume 10,000 Unit price: 0.51942 EUR |
| f. | Venue | Nasdaq First North Growth Market |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.